AVCNF
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.00 | $7M | -$971,854 |
| 2025 Q4 | -0.01 | $7M | -$198,766 |
| 2025 Q3 | -0.01 | $6M | -$865,192 |
| 2025 Q2 | -0.01 | $6M | -$215,276 |
| 2025 Q1 | 0.00 | $6M | -$157,710 |
| 2024 Q4 | 0.00 | $7M | -$548,009 |
| 2024 Q3 | -0.01 | $6M | -$268,723 |
| 2024 Q2 | -0.02 | $6M | -$2M |